TABLE 4-3.
COCCIDIOSTATS USED FOR TREATMENT AND PREVENTION OF COCCIDIOSIS IN SMALL RUMINANTS*
| COCCIDIOSTAT | DOSE | COMMENTS |
|---|---|---|
| Lasalocid | 20 to 30 g per ton of feed; 0.5 to 1 mg/kg body weight per head per day in feed or salt | Approved for use in sheep in the United States |
| Decoquinate | 0.5 mg/kg body weight per head per day in feed or salt | Approved for use in goats in the United States |
| Monensin | 10 to 30 g per ton of feed | Approved for use in goats in the United States; may be most effective choice for goats |
| Amprolium | 50 mg/kg body weight per head per day for 21 days (NOTE: This dose is five times the recommended calf dose) | Not approved for use in small ruminants in the United States; comes in liquid and crumble form; can potentially cause polioencephalomalacia at high doses and with prolonged administration |
| Sulfaquinoxaline | 13 mg/kg body weight per head per day as 0.015% solution in water for 3 to 5 days | Approved for use in sheep in the United States |
| Sulfamethazine | 119 to 238 mg/kg body weight per head per day in sheep; 50 g per ton of feed in goats | Not approved for use in small ruminants in the United States |
| Salinomycin | 382 g per ton of feed in goats | Not approved for use in small ruminants in the United States |
Not approved for dairy animals in the United States.
From Foreyt WJ: Coccidiosis and cryptosporidiosis in sheep and goats, Vet Clin North Am: Food Anim Pract 6(3):655 1990; Craig TM: Coccidiosis in small ruminants, Proceedings of the Small Ruminants for the Mixed Animal Practitioner, Western Veterinary Conference, 1998, Las Vegas, NV. Smith MC: Parasitic diseases of goats, Proceedings of the 1996 Symposium on the Health and Disease of Small Ruminants, 1996, Nashville, TN.
© 2002
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.